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Myocardial Involvement in Amyloidosis
Challenge and Opportunity*James E. Udelson, MDSEE PAGE 50W ith the increasing recognition of the het-erogeneity of patients who have heartfailure with preserved ejection fraction
(HFpEF), assessing the underlying etiology has
assumed substantial clinical importance. Large, ran-
domized trials using broad treatment paradigms for
HFpEF patients, such as those examining the role of
aldosterone antagonists (1), have not proven positive,
suggesting that a therapeutic approach needs to be
more targeted. Thus, diagnostic strategies that may
uncover a more directly treatable condition are of
great interest.
One underlying etiology that presents as the
HFpEF syndrome is cardiac amyloidosis. The current
understanding holds that cardiac amyloidosis is
usually the expression of 1 of 3 diseases associated
with the deposition of amyloid-type ﬁbrils in the
myocardium (2). Cardiac amyloid may be associated
with expansion of a plasma cell clone resulting in
deposition of immunoglobulin light chains in the
myocardium, known as AL amyloid. Cardiac amyloid
may also be the result of deposition of misfolded
transthyretin (TTR), a transport protein synthesized
by the liver. The TTR syndrome is divided into 2
categories: hereditary, or associated with misfolding
of wild-type TTR (2). The latter appears to mostly
be clinically manifest in older men. Recent evi-
dence indicates that these 3 major types of cardiac
amyloidosis may have distinct phenotypic and prog-
nostic proﬁles (2).
Treatment of AL amyloid is directed at the ex-
panded plasma cell clone. However, there are also*Editorials published in JACC: Cardiovascular Imaging reﬂect the views of
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amyloid, currently being tested in trials (3,4). Hence,
identiﬁcation of the presence of cardiac amyloid and
its speciﬁc etiology is assuming increasing importance.
The gold standard for diagnosis and assessment
of speciﬁc amyloid subtype is obtaining tissue
using endomyocardial biopsy. However, the exper-
tise needed for this technique limits it to centers
specializing in advanced heart failure. Thus, a non-
invasive imaging marker that can assist in selecting
patients most likely to have a high yield of bi-
opsy, or alternatively rule out the diagnosis with
a strong degree of conﬁdence, would be of clinical
importance.In this issue of iJACC, Lee et al. (5) report on a
positron emission tomography (PET) tracer known
as 11C-Pittsburgh B (PiB) for detection of cardiac
amyloidosis, in what is labeled as a pilot study. There
are several reports of the use of this agent for imaging
amyloid ﬁbrils in the brains of patients with Alz-
heimer’s disease (6). Its afﬁnity for amyloid ﬁbrils is
apparently related to the fact that it is derivative of
thioﬂavin-T, a ﬂuorescent dye used in the identiﬁca-
tion of amyloid ﬁbrils in various organs (7). An initial
report described cardiac uptake of 11C-PiB in a small
number of patients who had either AL or TTR cardiac
amyloidosis (8).
In this report, the investigators studied 22 patients
who had evidence of a monoclonal gammopathy and
also had a suggestion of cardiac involvement by
echocardiography or electrocardiography, or who had
biopsy-proven amyloid of a noncardiac organ. The
patients underwent PET/computed tomography (CT)
imaging to assess the presence and magnitude of 11C-
PiB uptake. Most also had endomyocardial biopsy,
echocardiography, and cardiac magnetic resonance
imaging (CMR). Ten referent control subjects who
were sex-matched but not well matched for age were
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61also studied with PET/CT 11C-PiB imaging in an
attempt to deﬁne a normal range.
Among the 15 patients with biopsy-proven cardiac
amyloid (all with the AL type), the 11C-PiB uptake
relative to the blood cavity was higher than in those
patients with negative biopsies. Figure 1 from the
paper (5) suggests that these results were driven by 5
or 6 of the 15 biopsy-positive patients with high
values. When using a cut-off value derived from the
normal subjects, the point estimate for sensitivity
was 87%, with speciﬁcity of 100%. Given the modest
number of patients, the conﬁdence intervals (CIs)
were wide.
The data on this agent are of real interest. Be-
sides the compelling reasons noted earlier to seek
out the diagnosis of cardiac amyloid and its speciﬁc
type, this agent appears to have a mechanism that,
in theory, could allow for a better delineation of the
magnitude of amyloid deposition within a particular
patient than available with prior imaging agents.
That would be of potentially great value in clinical
trials.
There are some important limitations to the con-
clusions that can be drawn from this dataset, some of
which are acknowledged by the authors. The patients
included are limited to those with AL amyloid,
although a previous report suggested that 11C-PiB is
also taken up in TTR amyloid (8). In such a small
dataset, misclassiﬁcation of disease status by the gold
standard test can have a major effect on the results. In
the 7 patient biopsy-negative patients, 4 had low
voltage on electrocardiogram, and some had unex-
plained left ventricular hypertrophy, raising the
question of sampling error in the biopsies. Finally,
typical of many early reports on imaging perfor-
mance, the focus of the discussion is on the point
estimates of the calculated performance characteris-
tics, as the authors refer to the “excellent” sensitivity
and speciﬁcity of this new agent. However, given the
small number of disease positive and disease nega-
tive patients, it is more appropriate to examine the
CIs, which suggest that the sensitivity and speciﬁcity
performance of this agent may range from unaccept-
able (lower CI boundary 58% and 56%, respectively)
to almost perfect (upper CI boundary 98% and 100%,
respectively). This illustrates why we need to be
circumspect about early data such as these, but we
must focus on the promise and potential to move
forward.
Other radionuclide tracers have been investigated
over the years as markers of cardiac amyloid. Begin-
ning more than 30 years ago, various bone-seeking
radiotracers have been examined by investigators
around the world (9). None has achieved widespreaduse, for a variety of reasons. One reason is that the
literature on performance characteristics is chal-
lenging to synthesize. There are heterogeneities in
patient populations as well as in the truth standards
used to parse the patients into disease positive and
disease negative subsets. Analytic methodologies also
vary, with early studies using qualitative assess-
ments, which are of course highly variable, whereas
more recent studies incorporate quantitative ana-
lytics (9). The present study by Lee et al. (5) illustrates
some of these issues. As noted, some of the patients
who were disease negative by biopsy had clinical
signs suggesting cardiac involvement, such as low
voltage on electrocardiography or unexplained hy-
pertrophy on echocardiography. Moreover, even
within the biopsy-positive disease subset, some of the
patients had been treated for AL amyloid, confound-
ing the assessment of tracer uptake and creating
additional small subsets of patients for analysis.
Nonetheless, there are some features of this new
agent that are attractive and suggest that further
research should be pursued. The apparent mechanism
of its uptake and retention may be more speciﬁc for
the cardiac amyloid inﬁltrative disease state than
prior agents. The use of PET/CT technology brings the
promise of more sophisticated analysis of uptake than
might be possible with planar or single-photon emis-
sion CT imaging of technetium-99m–based tracers.
In the dataset from Lee et al. (5), CMR was also
obtained, and the data appeared similar in overall
performance, although there was some discordance
between the ﬁndings of the radionuclide imaging
and the CMR results. The small size of the study
group here precludes rigorous comparisons. It has
been almost 10 years since the initial reports of the
use of CMR and gadolinium enhancement imaging in
cardiac amyloid (10), documenting the diffuse sub-
endocardial uptake pattern. Many reports also
involve modest numbers of patients, similar to the
radionuclide data. Although the application of CMR
techniques with gadolinium are precluded in pa-
tients with an important degree of renal dysfunction,
the evolving capability of quantitation of myocardial
extracellular volume fraction, which may be linked
to the magnitude of amyloid deposition, will drive
further interest and development.
As previously suggested, the emergence of treat-
ment possibilities for this heretofore progressive
syndrome, both for AL amyloid and, more recently,
TTR amyloid, makes the development of imaging
strategies to screen for the presence of and possibly
quantify the magnitude of cardiac involvement a
highly compelling and important opportunity for the
imaging community. These pilot data on the use of
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62the 11C-PiB agent represent a small ﬁrst step in such a
direction. Ideally, imaging markers such as this agent
would be incorporated into clinical trials of new
treatment strategies as a baseline measure, so that
analyses could illuminate whether imaging may
identify patients with better or lesser responses to the
new therapy. Unfortunately, imaging and therapeu-
tics most often develop in parallel rather than in
concert. To the extent that we, as a community,
can change this approach would have a potentiallyimportant effect on the use of imaging to help better
target therapeutics and improve care for patients
with challenging disease states such as cardiac
amyloidosis.
REPRINT REQUESTS AND CORRESPONDENCE: Dr.
James E. Udelson, Box 70, Division of Cardiology,
Tufts Medical Center, 800 Washington Street,
Boston, Massachusetts 02111. E-mail: JUdelson@
tuftsmedicalcenter.org.RE F E RENCE S1. Pitt B, Pfeffer MA, Assmann SF, Boineau R,
et al. Spironolactone for heart failure with
preserved ejection fraction. N Engl J Med 2014;
370:1383–92.
2. Rapezzi C, Merlini G, Quarta CC, et al. Systemic
cardiac amyloidoses: disease proﬁles and clinical
courses of the 3 main types. Circulation 2009;120:
1203–12.
3. ClinicalTrials.gov. Safety and efﬁcacy of tafami-
dis in patients with transthyretin cardiomyopathy
(ATTR-ACT). Available at: http://www.clinicaltrials.
gov/show/NCT01994889. Accessed September
25, 2014.
4. ClinicalTrials.gov. APOLLO: the study of an
investigational drug, Patisiran (ALN-TTR02), forthe treatment of transthyretin (TTR)-mediated
amyloidosis. Available at: http://www.clinicaltrials.
gov/show/NCT01960348. Accessed September
25, 2014.
5. Lee S-P, Lee ES, Choi H, et al. 11C-Pittsburgh B
PET imaging in cardiac amyloidosis. J Am Coll
Cardiol Img 2015;8:50–9.
6. Klunk WE, Engler H, Nordberg A, et al. Im-
aging brain amyloid in Alzheimer’s disease with
Pittsburgh Compound-B. Ann Neurol 2004;55:
306–19.
7. Biancalana M, Koide S. Molecular mechanism of
thioﬂavin-T binding to amyloid ﬁbrils. Biochim
Biophys Acta 2010;1804:1405–12.8. Antoni G, Lubberink M, Estrada S, et al. In vivo
visualization of amyloid deposits in the heart with
11C-PIB and PET. J Nucl Med 2013;54:213–20.
9. Chen W, Dilsizian V. Molecular imaging of
amyloidosis: will the heart be the next target after
the brain? Curr Cardiol Rep 2012;14:226–33.
10. Maceira AM, Joshi J, Prasad SK, et al. Cardio-
vascular magnetic resonance in cardiac amyloid-
osis. Circulation 2005;111:186–93.KEY WORDS cardiac amyloidosis, cardiac
magnetic resonance, echocardiography,
Pittsburgh B compound, positron emission
tomography
